CNS Pharmaceuticals director Michal Fisher acquires $10,000 of common shares
Reuters2026/08/18 13:01- CNS Pharmaceuticals director Michal Fisher bought 2,000 common shares at USD 5 per share.
- Direct holding rose to 2,000 shares following the purchase.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
